Addition solidifies commitment to delivering comprehensive solutions worldwide, company says.
Spaulding Clinical, a clinical research organization (CRO), has announced the addition of ADME (absorption, distribution, metabolism, and excretion) clinical trials to its list of services. According to the company, ADME studies are vital components of drug development, providing critical insights into the behavior of drugs within the human body.
“With the addition of ADME studies to our suite of services plus hired staff with over 60 years combined experience in conducting these trial types, Spaulding Clinical is positioned to better support our clients in making informed decisions during drug development,” said Cassandra Erato, CEO, Spaulding Clinical. “These trials play a pivotal role in understanding the behavior and fate of a drug in the body, allowing researchers to optimize dosage, assess potential drug-drug interactions, and enhance overall drug safety profiles.”
Reference: Spaulding Clinical Expands Services to Include ADME Clinical Trials. Spaulding Clinical. June 22, 2023.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.